Stock COLL COLLEGIUM PHARMACEUTICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
33.14 USD +2.19% Intraday chart for Collegium Pharmaceutical, Inc. -3.24% +7.67%
May. 13 Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program MT
May. 10 Needham Downgrades Collegium Pharmaceutical to Hold From Buy MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program
MT
Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated
MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q1 EPS $1.45, vs. Street Est of $1.47
MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024
CI
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
CI
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes
MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase
MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26
MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Collegium Pharmaceutical Expects Net Product Revenue of up to $595 Million in 2024
MT
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 4, 2023.
CI
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $150 million worth of its shares.
CI
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2024
CI
Collegium Pharmaceutical, Inc. authorizes a Buyback Plan.
CI
Collegium Pharmaceutical, Inc.'s Equity Buyback announced on January 4, 2023, has expired with 3,088,069 shares, representing 9.09% for $75 million.
CI
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q3 EPS $1.34, vs. Street Est of $1.24
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COLL Stock
  4. News Collegium Pharmaceutical, Inc.
  5. Highlights